Apoquel

Country: European Union

Language: Estonian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
21-01-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
21-01-2022
Public Assessment Report Public Assessment Report (PAR)
21-01-2022

Active ingredient:

oklatsitiniibmaleaat

Available from:

Zoetis Belgium SA

ATC code:

QD11AH90

INN (International Name):

oclacitinib maleate

Therapeutic group:

Koerad

Therapeutic area:

Dermatiidi ained, välja arvatud kortikosteroidid

Therapeutic indications:

- Treatment of pruritus associated with allergic dermatitis in dogs. - Treatment of clinical manifestations of atopic dermatitis in dogs.

Product summary:

Revision: 8

Authorization status:

Volitatud

Authorization date:

2013-09-12

Patient Information leaflet

                                27
B. PAKENDI INFOLEHT
28
PAKENDI INFOLEHT
APOQUEL 3,6 MG ÕHUKESE POLÜMEERIKATTEGA TABLETID KOERTELE
APOQUEL
5,4 MG ÕHUKESE POLÜMEERIKATTEGA TABLETID KOERTELE
APOQUEL 16 MG ÕHUKESE POLÜMEERIKATTEGA TABLETID KOERTELE
1.
MÜÜGILOA HOIDJA NING, KUI NEED EI KATTU, RAVIMIPARTII VABASTAMISE
EEST VASTUTAVA TOOTMISLOA HOIDJA NIMI JA AADRESS
Müügiloa hoidja:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIA
Partii vabastamise eest vastutav tootja:
Pfizer Italia S.R.L.
Via del Commercio 25/27
63100 Marino Del Tronto (AP)
ITAALIA
või
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIA
2.
VETERINAARRAVIMI NIMETUS
Apoquel 3,6 mg õhukese polümeerikattega tabletid koertele
Apoquel 5,4 mg õhukese polümeerikattega tabletid koertele
Apoquel 16 mg õhukese polümeerikattega tabletid koertele
oklatsitiniib
3.
TOIMEAINETE JA ABIAINETE SISALDUS_ _
_ _
Iga õhukese polümeerikattega tablett sisaldab 3,6 mg, 5,4 mg või 16
mg oklatsitiniibi
oklatsitiniibmaleaadina.
Valged kuni valkjad ovaalse kujuga polümeerikattega tabletid, mille
mõlemal küljel on poolitusjoon ja
märge „AQ” ja „S”, „M” või „L”
Tähed „S”, „M” ja „L” viitavad tablettide erinevatele
tugevustele: 3,6
mg tablettidel on „S”, 5,4 mg tablettidel „M” ja 16 mg
tablettidel „L”.
Tableti saab jagada võrdseteks annusteks.
4.
NÄIDUSTUS(ED)
Allergilise dermatiidiga kaasneva nahasügeluse ravi koertel.
Atoopilise dermatiidi kliiniliste sümptomite ravi koertel.
5.
VASTUNÄIDUSTUSED
Mitte kasutada, kui esineb ülitundlikkust oklatsitiniibi või ravimi
ükskõik milliste abiainete suhtes.
Mitte kasutada alla 12 kuu vanustel või alla 3 kg kaaluvatel koertel.
29
Mitte kasutada immuunpuudulikkuse (nt hüperadrenokortitsismi) või
progresseeruva pahaloomulise
kasvaja kahtluse korral, sest toimeaine mõju sellistele seisunditele
ei ole teada.
6.
KÕRVALTOIMED
Sagedased kõrvaltoimed, mida täheldati väliuuringus 16. päevani,
on toodud välja allolevas tabelis:
16. päevani atoopilise dermatiidi
uur
                                
                                Read the complete document

Summary of Product characteristics

                                1
LISA I
RAVIMI OMADUSTE KOKKUVÕTE
2
1.
VETERINAARRAVIMI NIMETUS
Apoquel 3,6 mg õhukese polümeerikattega tabletid koertele
Apoquel
5,4 mg õhukese polümeerikattega tabletid koertele
Apoquel 16 mg õhukese polümeerikattega tabletid koertele
2.
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS
TOIMEAINE:
Iga õhukese polümeerikattega tablett sisaldab:
Apoquel 3,6 mg:
3,6 mg oklatsitiniibi (oklatsitiniibmaleaadina)
Apoquel 5,4 mg:
5,4 mg oklatsitiniibi (oklatsitiniibmaleaadina)
Apoquel 16 mg:
16 mg oklatsitiniibi (oklatsitiniibmaleaadina)
Abiainete täielik loetelu on esitatud lõigus 6.1.
3.
RAVIMVORM
Õhukese polümeerikattega tabletid.
Valged kuni valkjad ovaalse kujuga polümeerikattega tabletid, mille
mõlemal küljel on poolitusjoon ja
märge „AQ” ja „S”, „M” või „L”. Tähed „S”,
„M” ja „L” viitavad tablettide erinevatele tugevustele: 3,6
mg tablettidel on „S”, 5,4 mg tablettidel „M” ja 16 mg
tablettidel „L”.
Tableti saab jagada võrdseteks annusteks.
4.
KLIINILISED ANDMED
4.1
LOOMALIIGID
Koer.
4.2
NÄIDUSTUSED, MÄÄRATES KINDLAKS VASTAVAD LOOMALIIGID
Allergilise dermatiidiga kaasneva nahasügeluse ravi koertel.
Atoopilise dermatiidi kliiniliste sümptomite ravi koertel.
4.3
VASTUNÄIDUSTUSED
Mitte kasutada, kui esineb ülitundlikkust toimeaine või ravimi
ükskõik milliste abiainete suhtes.
Mitte kasutada alla 12 kuu vanustel või alla 3 kg kaaluvatel koertel.
Mitte kasutada immuunpuudulikkuse (nt hüperadrenokortitsismi) või
progresseeruva pahaloomulise
kasvaja kahtluse korral, sest toimeaine mõju sellistele seisunditele
ei ole teada.
4.4
ERIHOIATUSED IGA LOOMALIIGI KOHTA
Ei ole.
4.5
ETTEVAATUSABINÕUD
Ettevaatusabinõud kasutamisel loomadel
Oklatsitiniib toimib immuunsüsteemile ja võib suurendada
vastuvõtlikkust nakkushaigustele ning
kiirendada kasvajaliste seisundite edasiarenemist. Seetõttu peab
Apoqueli tablette tarvitavaid koeri
regulaarselt jälgima nakkushaiguste ja kasvajate suhtes.
3
Kui oklatsitiniibi kasutatakse allergilise dermatiidiga kaasneva
nahasü
                                
                                Read the complete document

Similar products

Active ingredient oklatsitiniibmaleaat

oklatsitiniibmaleaat

ATC code QD11AH90

QD11AH90

Marketed by Zoetis Belgium SA

Zoetis Belgium SA

INN (International Name) oclacitinib maleate

oclacitinib maleate

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-01-2022
Public Assessment Report Public Assessment Report Bulgarian 21-01-2022
Patient Information leaflet Patient Information leaflet Spanish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Spanish 21-01-2022
Public Assessment Report Public Assessment Report Spanish 21-01-2022
Patient Information leaflet Patient Information leaflet Czech 21-01-2022
Summary of Product characteristics Summary of Product characteristics Czech 21-01-2022
Public Assessment Report Public Assessment Report Czech 21-01-2022
Patient Information leaflet Patient Information leaflet Danish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Danish 21-01-2022
Public Assessment Report Public Assessment Report Danish 21-01-2022
Patient Information leaflet Patient Information leaflet German 21-01-2022
Summary of Product characteristics Summary of Product characteristics German 21-01-2022
Public Assessment Report Public Assessment Report German 21-01-2022
Patient Information leaflet Patient Information leaflet Greek 21-01-2022
Summary of Product characteristics Summary of Product characteristics Greek 21-01-2022
Public Assessment Report Public Assessment Report Greek 21-01-2022
Patient Information leaflet Patient Information leaflet English 21-01-2022
Summary of Product characteristics Summary of Product characteristics English 21-01-2022
Public Assessment Report Public Assessment Report English 21-01-2022
Patient Information leaflet Patient Information leaflet French 21-01-2022
Summary of Product characteristics Summary of Product characteristics French 21-01-2022
Public Assessment Report Public Assessment Report French 21-01-2022
Patient Information leaflet Patient Information leaflet Italian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Italian 21-01-2022
Public Assessment Report Public Assessment Report Italian 21-01-2022
Patient Information leaflet Patient Information leaflet Latvian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Latvian 21-01-2022
Public Assessment Report Public Assessment Report Latvian 21-01-2022
Patient Information leaflet Patient Information leaflet Lithuanian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-01-2022
Public Assessment Report Public Assessment Report Lithuanian 21-01-2022
Patient Information leaflet Patient Information leaflet Hungarian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 21-01-2022
Public Assessment Report Public Assessment Report Hungarian 21-01-2022
Patient Information leaflet Patient Information leaflet Maltese 21-01-2022
Summary of Product characteristics Summary of Product characteristics Maltese 21-01-2022
Public Assessment Report Public Assessment Report Maltese 21-01-2022
Patient Information leaflet Patient Information leaflet Dutch 21-01-2022
Summary of Product characteristics Summary of Product characteristics Dutch 21-01-2022
Public Assessment Report Public Assessment Report Dutch 21-01-2022
Patient Information leaflet Patient Information leaflet Polish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Polish 21-01-2022
Public Assessment Report Public Assessment Report Polish 21-01-2022
Patient Information leaflet Patient Information leaflet Portuguese 21-01-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 21-01-2022
Public Assessment Report Public Assessment Report Portuguese 21-01-2022
Patient Information leaflet Patient Information leaflet Romanian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Romanian 21-01-2022
Public Assessment Report Public Assessment Report Romanian 21-01-2022
Patient Information leaflet Patient Information leaflet Slovak 21-01-2022
Summary of Product characteristics Summary of Product characteristics Slovak 21-01-2022
Public Assessment Report Public Assessment Report Slovak 21-01-2022
Patient Information leaflet Patient Information leaflet Slovenian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 21-01-2022
Public Assessment Report Public Assessment Report Slovenian 21-01-2022
Patient Information leaflet Patient Information leaflet Finnish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Finnish 21-01-2022
Public Assessment Report Public Assessment Report Finnish 21-01-2022
Patient Information leaflet Patient Information leaflet Swedish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Swedish 21-01-2022
Public Assessment Report Public Assessment Report Swedish 21-01-2022
Patient Information leaflet Patient Information leaflet Norwegian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 21-01-2022
Patient Information leaflet Patient Information leaflet Icelandic 21-01-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 21-01-2022
Patient Information leaflet Patient Information leaflet Croatian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Croatian 21-01-2022
Public Assessment Report Public Assessment Report Croatian 21-01-2022

Search alerts related to this product

Alerts Apoquel oklatsitiniibmaleaat oclacitinib maleate

Apoquel oklatsitiniibmaleaat oclacitinib maleate

View documents history

Documents history Documents history

Apoquel